Improved local control by surgery and paclitaxel‐based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non‐randomized study

2008 ◽  
Vol 98 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Feng‐Ming Hsu ◽  
Chia‐Chi Lin ◽  
Jang‐Ming Lee ◽  
Yih‐Leong Chang ◽  
Chih‐Hung Hsu ◽  
...  
2021 ◽  
Author(s):  
jianyong sun ◽  
weiju huang ◽  
jingbin chen ◽  
yaohong zhang

Abstract Purpose: This retrospective study was designed to analyze the effect and prognostic factors of whole-course conformal radiotherapy and late-course accelerated hyperfractionation radiotherapy (LCAFRT) for esophageal squamous cell carcinoma (ESCC).Methods and materials: A total of 110 patients with ESCC received whole-course conformal radiotherapy and LCAFRT in Chaozhou City People’s hospital between May 2004 and January 2015. All patients received conventional conformal radiotherapy of 2 Gy per day up to 30–40 Gy, followed by accelerated hyperfractionation conformal radiotherapy using reduced fields at 1.5 Gy/fraction twice a day up to 24–39 Gy, with a total dose of 60–69 Gy.Results: Median follow-up was 85 months (2–170 months). The one-, three-, and five-year survival rates were 81.82%, 46.36%, and 41.82%, respectively. The median survival time was 31.8 months. The local control rates for the whole group at 1, 3, and 5 years were 82.73%, 70%, and 68.18%, respectively. There were no significant differences among 1-, 3-, and 5-year survival rates and local control rates between the three-dimensional conformal radiotherapy group and intensity-modulated radiotherapy group. The main reactions to acute radiotherapy were acute radiation tracheitis, esophagitis, and pneumonia. Multivariate analysis showed that the tumor location and TNM stage were independent prognostic factors.Conclusion: The results from this study showed that whole-course conformal radiotherapy and LCAFRT for ESCC can further improve survival and local control with a tolerable acute reaction compared to previous studies. Local recurrence and distant metastasis are the main failure modes of treatment.


2020 ◽  
Author(s):  
Ihsuan Tseng ◽  
Yun Chen ◽  
Zhengfei Zhu ◽  
Weixin Zhao ◽  
Qi Liu ◽  
...  

Abstract Background: Concurrent chemoradiotherapy (CCRT) is a standard treatment for inoperable locally advanced esophageal carcinoma. However, there exists a group of patients who are intolerable to intravenous chemotherapy for the old age or with serious comorbidities. S-1 is an oral fluorouracil derivative with well tolerance than 5-fluorouracil. The ESO-Shanghai 7 trial aimed to access the safety and efficacy of S-1 combined with radiotherapy for esophageal squamous cell carcinoma (ESCC) patients who are elderly or with serious comorbidities.Methods: 105 ESCC patients with old age or serious comorbidities will be enrolled in this prospective, single-arm phase 2 clinical trial. Patients will receive S-1 orally at a dose of 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) twice daily for 28 days. The concurrent radiotherapy dose is 61.2 Gy delivered in 34 fractions. The primary endpoints are 3-yr local control and number and grade of participants with adverse events, and the secondary endpoint is overall survival. Discussion: The aim of this phase 2 trial is to determine the tolerance and efficacy of S-1 concurrent with radiotherapy for ESCC patients with old age or serious comorbidities. A very promising 3-yr local control should beat least 60% from the clinical point of view.Trial registration: ClinicalTrials.gov, NCT01831531. Registered 29 March 2013, https://clinicaltrials.gov/ct2/show/NCT01831531?term=NCT01831531&draw=2&rank=1


2015 ◽  
Vol 106 (4) ◽  
pp. 407-412 ◽  
Author(s):  
Masayuki Shinoda ◽  
Nobutoshi Ando ◽  
Ken Kato ◽  
Satoshi Ishikura ◽  
Hoichi Kato ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document